Market Cap (In SEK)
19.36 Million
Revenue (In SEK)
-
Net Income (In SEK)
-39.2 Million
Avg. Volume
894.45 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.065-5.64
- PE
- -
- EPS
- -
- Beta Value
- 1.28
- ISIN
- DK0061031895
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Francois Regis Martelet M.D.
- Employee Count
- -
- Website
- https://www.scandiononcology.com
- Ipo Date
- 2018-11-08
- Details
- Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
More Stocks
-
2722
-
KLBN3Klabin S.A.
KLBN3
-
3RB
-
086790Hana Financial Group Inc.
086790
-
002283
-
1140Bank Albilad
1140
-
002810Shandong Head Group Co.,Ltd.
002810
-
TAWNF